Ray McDermott

30.4k citations
150 papers · 6.5k · 3 hit papers · h-index 30

Impact in

Papers in

    • Colorectal Cancer Treatments and Studies 18
    • Cancer Immunotherapy and Biomarkers 13
    • PARP inhibition in cancer therapy 9
    • Prostate Cancer Treatment and Research 29
    • Lung Cancer Treatments and Mutations 14
    • Prostate Cancer Diagnosis and Treatment 9

Ray McDermott

144 papers receiving 6.4k citations

Ray McDermott's Hit Papers

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 2022 · 167 citations
1670+3+6Years since publication50010001.5k2.0k

Peers

Ray McDermott
Comparison fields: 5 of 135
  • Oncology 3.3k
  • Pathology and Forensic Medicine 1.3k
  • Cancer Research 1.0k
  • Pulmonary and Respiratory Medicine 1.1k
  • Immunology 773
Replace George Fountzilas with:
George Fountzilas Greece
Anthony Elias United States
Robert A. Burger United States
Mark F. Brady United States
Timothy Perren United Kingdom
Karl C. Podratz United States
Martin F. Fey Switzerland
Seppo Pyrhönen Finland
Jean‐Philippe Spano France
Suzanne George United States
Ray McDermott relative to George Fountzilas Greece George Fountzilas's profile →
Citations per field
00.5×3.2×
George Fountzilas · 1×
Citations per year

Countries citing papers authored by Ray McDermott

Since Specialization
Citations

This map shows the geographic impact of Ray McDermott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ray McDermott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ray McDermott more than expected).

Fields of papers citing papers by Ray McDermott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ray McDermott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ray McDermott. The network helps show where Ray McDermott may publish in the future.

Co-authors

The 25 scholars most cited alongside Ray McDermott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ray McDermott Line = papers co-authored together Ray McDermott links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 150 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Hit paper breakdown →
20172014
2
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Hit paper breakdown →
20181455
3 2012383
4
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
Hit paper breakdown →
2022167
5 2013137
6 2013110
7 199997
8
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
202296
9 200593
10 201485
11 201681
12 200076
13 201176
14 201970
15 200258
16 201756
17 201953
18 201051
19 201450
20 200050

About Ray McDermott

Ray McDermott is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Molecular Biology and Cancer Research, having authored 150 papers that have together received 6.5k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (29 papers), Colorectal Cancer Treatments and Studies (18 papers), Lung Cancer Treatments and Mutations (14 papers), Cancer Immunotherapy and Biomarkers (13 papers), Radiopharmaceutical Chemistry and Applications (12 papers), Cancer Genomics and Diagnostics (9 papers), Prostate Cancer Diagnosis and Treatment (9 papers) and PARP inhibition in cancer therapy (9 papers). The work is most often cited by research in Oncology (3.3k citations), Pathology and Forensic Medicine (1.3k citations), Cancer Research (1.0k citations), Pulmonary and Respiratory Medicine (1.1k citations) and Immunology (773 citations). Ray McDermott has collaborated with scholars based in Ireland, United States and Australia. Frequent co-authors include Scott Kopetz, Thierry André, Sara Lonardi, Michael J. Overman, Andrew Hill, Rebecca A. Moss, Jean-Marie Ledeine, Z. Alexander Cao, Heinz‐Josef Lenz and Michael A. Morse. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Cancers, ESMO Open and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact